-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Author Index: T

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Takagi, S.
1453 - Combined Targeting Patient-Specific Anti-Apoptotic Molecules and CXCR4-Expressing CAR-T Cells Eliminated High-Inflammation State Leukemia with Poor-Prognostic Mutations
2162 - Novel Insights into Predictors, Optimized Treatments, and Prognosis Factors for Virus-Induced Hemorrhagic Cystitis Post-Hematopoietic Stem Cell Transplantation: A Single-Institution Study of 427 Japanese Patients
2189 - Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL
3485 - What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes
3508 - Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation
4920 - Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status
4926 - Single Cord Blood Transplantation with Fludarabine, Busulfan and Melphalan Is Crucial Therapeutic Strategy for AML Not in Remission: A Single-Center Retrospective Study of 286 Patients Including Prognostic Factor Analysis
4933 - Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms
Takahashi, K.
56 - Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia
61 - Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones
219 - A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update
346 - Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant
446 - Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine
642 - Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in IDH1-Mutated Myeloid Malignancies
726 - Mitigating Therapy-Related Myeloid Neoplasia in p53-Mutant Clones through Targeted DNA Repair Pathway Inhibition with PARP Inhibitors
728 - Older Age and TP53 Mutations Are Predictors for the Development of Therapy-Related Myeloid Neoplasms in Adults Undergoing Frontline Therapy for Acute Lymphoblastic Leukemia
734 - A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
837 - Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse
841 - Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3-Tyrosine Kinase Domain (TKD) Mutations
882 - Novel p53 Mutant Mouse Model Recapitulates the Biology of Human Therapy-Related Myeloid Neoplasms
1011 - Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
1441 - Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update
1442 - Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia
1461 - Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens
1816 - Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms
1837 - Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies
1855 - Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL
2438 - Neighborhood Disadvantage Impacts Outcomes in Patients with Myelodysplastic Syndromes across Different Racial Backgrounds
2883 - Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials
2896 - Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy
3212 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome
3817 - Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods
4263 - Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
4272 - Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
4293 - Patterns of Relapse Following Venetoclax-Based Therapies of Differing Intensity in Acute Myeloid Leukemia
4601 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome
1527.2 - Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation
Tam, C. S.
341 - Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma
860 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study
868 - Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T–Naive and CAR-T–Exposed Patients
885 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study
1012 - Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101
1649 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study
3031 - Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study
3255 - Deep and Sustained Responses in Patients with CLL Treated with Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report from the Zanubrutinib Extension Study
4384 - Marginal Zone Lymphoma Is Associated with Dysregulated Peripheral Blood Immunity Which Is Not Changed By Ibrutinib-Venetoclax Treatment
4412 - Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)
Tan, C. R.
248 - Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease
671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
672 - Immune-MRD Status Informs Tumor-MRD Outcome Prognostication in Multiple Myeloma Patients on Lenalidomide Maintenance
704 - Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis
1944 - Impact of Absolute Lymphocyte Count at Pre-Apheresis and Pre-Lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)
3343 - Evaluation of the Safety and Efficacy of Denosumab in Patients with Multiple Myeloma and Severe Renal Impairment; Results from an IMWG Bone Subcommittee Study
3362 - Daratumumab Versus Lenalidomide As Maintenance Therapy in Newly Diagnosed Multiple Myeloma – Interim Efficacy Results of a Randomized Clinical Trial
3368 - Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium
3760 - Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment: Results from a Multicenter Chart Review Study
4735 - Frailty and Outcomes after Bispecific T-Cell Engager Therapy for Patients with Relapsed/Refractory Multiple Myeloma
4850 - Manufacture of Anti-BCMA CAR T Cell Is Feasible after Salvage Autologous or Allogeneic Hematopoietic Stem Cell Transplantation
5166 - Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee
Tang, G.
735 - Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse
1461 - Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens
1971 - Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma
3038 - Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma
3246 - Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53-Mutated Chronic Lymphocytic Leukemia
3344 - Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant
4224 - Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory
4263 - Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
4306 - Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy
4336 - Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1-mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease
Tasian, S. K.
369 - Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro, In Vivo, and Ex Vivo Anti-Leukemia Activity
370 - Gilteritinib Augments Preclinical FLT3 and CD19 CAR T Cell Immunotherapy in High-Risk Pediatric Leukemias
1361 - Targeting HMGA1 Epigenetic Regulators and Downstream ETV5 Pathways with Histone Deacetylase Inhibitors in Combination Therapy for Relapsed, Pediatric B-ALL
1407 - A Novel Antibody-Drug Conjugate Targeting the CD179a Component of the Surrogate Light Chain for the Treatment of B-Cell Acute Lymphoblastic Leukemia/Lymphoma
1455 - KMT2A-Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation
2789 - A Novel Approach Combining Type II JAK Inhibitor Chz-868 with Nutrient Restriction to Augment Cell Death in Philadelphia like Acute Lymphoblastic Leukemia
3424 - Co-Targeting of the Thymic Stromal Lymphopoietin Receptor to Decrease Immunotherapeutic Resistance in CRLF2-Rearranged Ph-like and Down Syndrome ALL
4233 - Molecular Features, Treatments and Outcomes for Pediatric AML Patients from APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial
2828.1 - Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2)
4265.3 - APAL2020K/ITCC-101: A Phase I Trial of the Menin Inhibitor Ziftomenib in Combination with Chemotherapy in Children with Relapsed/Refractory KMT2A-rearranged, NUP98-rearranged, or NPM1-mutant Acute Leukemias
4265.4 - PEPN2312: A Pediatric Early Phase Clinical Trials Network (PEP-CTN) Phase 1 Trial of Imetelstat with Fludarabine/Cytarabine in Pediatric Patients with Relapsed/Refractory AML, MDS, or JMML
Teachey, D. T.
1 - Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731
313 - Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma
315 - Prognostic Impact of t(1;19) in Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Treated on Contemporary Children’s Oncology Group (COG) Protocols
633 - The Role of an Inflammatory Phenotype in Driving Clonal Evolution in B-Acute Lymphoblastic Leukemia
634 - TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL
725 - Aberrant Stemness Transcription Signature Unveils a Mechanism of Chemotherapy Resistance through Blunting p53-Mediated Response in Acute Myeloid Leukemia
1464 - Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL
2813 - Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
2830 - A Non-Canonical Lymphoblast in Refractory Childhood T-Cell Acute Lymphoblastic Leukemia
2838 - Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages
3454 - Preinfusion Risk Factors for the Development of Severe Immune Effector Cell Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Infusion in Pediatric Patients
4195 - Additional Induction Intrathecal Cytarabine for Patients with CNS2 Disease at Diagnosis Is Not Beneficial for Patients with B-ALL Treated on Children's Oncology Group Protocols AALL0932 and AALL1131
Tedeschi, A.
Tefferi, A.
244 - TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance
657 - A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia
1785 - Revised International Working Group Risk Model for Survival in Polycythemia Vera
1795 - Homozygosity of the JAK2 46/1 or GGCC Haplotype Contributes to Phenotype and Outcome Diversity Among Patients with Polycythemia Vera
1797 - The Mutational Landscape of Polycythemia Vera and Its Phenotypic and Prognostic Correlates
1798 - Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials
1820 - Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)
1827 - Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform
2852 - Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
3169 - Monocytosis Is an Independent Risk Factor for Survival in Essential Thrombocythemia - a Revised Triple-a Prognostic Score (AAA+A) Based on Age and Absolute Monocyte, Neutrophil, and Lymphocyte Counts
3171 - Autoimmune or Inflammatory Diseases in 1,968 Consecutive Patients with Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcome and Co-Morbidities
3176 - Cytogenetic Abnormalities in Polycythemia Vera: Phenotypic Correlates and Prognostic Relevance in 669 Informative Cases
3183 - Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41MT Germline Predisposition Syndrome
3185 - Thrombosis Risk Assessment in Polycythemia Vera (TRAP): A 4,636-Patient-Year Analysis of Arterial and Venous Thrombosis in Low-Risk Patients
3204 - Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
3218 - PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations
4247 - Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
4552 - Cancers in Polycythemia Vera and Essential Thrombocythemia: A before and after Diagnosis Survey and Analysis of Risk Factors
4586 - PHF6 Mutation in Chronic Myelomonocytic Leukemia Is Associated with Chronic Thrombocytopenia and Predicts Superior Overall and Leukemia-Free Survival
4593 - Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)
4594 - TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors
Terpos, E.
361 - Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study
487 - Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study
490 - A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma
1020 - Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies
1600 - Genomic Characterization of Ibrutinib-Resistant Waldenström’s Macroglobulinemia
1603 - The Combined Treatment of Btkis with Venetoclax Exhibits an Enhanced Therapeutic Effect on Waldenström Macroglobulinemia Cells Bearing CXCR4 Mutations
1948 - Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients
1991 - Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group
3285 - Circular RNA Profiling Using High-Accuracy Long-Read Nanopore Sequencing of Multiple Myeloma Cell Lines Reveals the Wide Diversity of the Circular Transcriptome
3343 - Evaluation of the Safety and Efficacy of Denosumab in Patients with Multiple Myeloma and Severe Renal Impairment; Results from an IMWG Bone Subcommittee Study
3361 - Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group
3380 - Less Is More: Deciphering the Association between Ocular Adverse Events and Clinical Activity of Belantamab Mafodotin in Multiple Myeloma
4397 - Clinical Outcomes in Consecutive Newly Diagnosed Patients with Waldenstrom’s Macroglobulinemia Treated with Different Regimens in the Real-World Setting
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
4674 - Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis
4675 - Risk and Patterns of Progression Among Smoldering Myeloma Patients after the Implementation of New Criteria and Modern Imaging
4694 - Measurable Residual Disease and Peripheral Residual Disease to Assess Treatment Response in Real-World Patients with Newly Diagnosed Multiple Myeloma
4696 - Evaluating Minimal Residual Disease Negativity As a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
4715 - Sequential Whole Body Low Dose CTs in Patients with Smoldering Multiple Myeloma Identify Early Progression and May Improve Patient Outcomes
4724 - Early Treatment Response Assessment with Sequential Whole Body Magnetic Resonance Imaging in Patients with Newly Diagnosed Multiple Myeloma
Theodorakakou, F.
361 - Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study
490 - A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma
889 - Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis
1017 - Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants
1020 - Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies
1927 - Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: An Updated Analysis of a Phase 2 Study By the European Myeloma Network
1934 - Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)
1948 - Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients
1979 - Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
1991 - Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group
3328 - An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response
3361 - Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group
3380 - Less Is More: Deciphering the Association between Ocular Adverse Events and Clinical Activity of Belantamab Mafodotin in Multiple Myeloma
4397 - Clinical Outcomes in Consecutive Newly Diagnosed Patients with Waldenstrom’s Macroglobulinemia Treated with Different Regimens in the Real-World Setting
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
4674 - Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis
4675 - Risk and Patterns of Progression Among Smoldering Myeloma Patients after the Implementation of New Criteria and Modern Imaging
4724 - Early Treatment Response Assessment with Sequential Whole Body Magnetic Resonance Imaging in Patients with Newly Diagnosed Multiple Myeloma
Thieblemont, C.
239 - Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group
474 - Post-Therapeutic Tumor Losses of B-Cell Receptor Components CD20/CD19, a New Challenge in the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
575 - Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa
577 - Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma
867 - Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
1596 - Predictive Power of Early, Sequential Minimal Residual Disease and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Monitoring in Young Patients with Mantle Cell Lymphoma in the Lyma Trial: A Lysa Study
3034 - Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
3110 - Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial
3115 - Prior Bendamustine (Benda) Exposure Did Not Impact Clinical Outcomes and Decreased CD4+ but Not CD8+ T-Cells in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with the Bispecific Antibody Epcoritamab (Epcor)
3124 - CAR T-Cells Treatment for Relapsed/Refractory B-Cell Lymphoma Is Effective and Safe in People Living with HIV (PLWH): A Lysa Study from the Descar-T Registry
3241 - Prognosis of the IGLV3-21R110 Mutation in a Real-Life Chronic Lymphocytic Leukemia Cohort
3256 - Preemptive Therapy with Venetoclax for High-Risk Stage a CLL Patients: First Analysis of Prevene, a Phase II Trial of the Filo Group
4467 - Long-Term Follow-up Study of Patients Aged 80 Years or Older Treated By Attenuated Chemotherapy Mini-CHOP Plus Anti-CD20 for DLBCL, Update of the LNH03-7B and LNH09-7B Lysa Trials
4480 - 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma
4491 - Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy
4505 - Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial
Thiruvengadam, S. K.
470 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
524 - Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma
526 - Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
1668 - Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma – International, Multi-Center Real-World Experience
1729 - Devimistat Results in a Low Complete Remission Rate in Heavily Pre-Treated Burkitt Lymphoma
2276 - The Clinical Impact and Cost-Effectiveness of PET-Based and Ctdna-Based Evaluation at End-of-Therapy after Frontline Treatment of DLBCL
3127 - Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease
3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
3638 - Serious Adverse Drug Reactions (sADRs) Involving Hematology and Resulting in Black Box Warnings or FDA Non-Approval: Results from the First Quarter Century of RADAR/Sonar
3654 - Changes in Treatment Patterns over Time Among Real-World Patients with Follicular Lymphoma at Predominantly Community Facilities in the US
1674.1 - Trial in Progress: Open-Label Phase 1 Study to Evaluate Safety of SGN-35C in Adults with Select Relapsed/Refractory Lymphomas (SGN35C-001)
1742.1 - A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Thomas, I.
55 - A Randomized Comparison of CPX-351 and FLAG-Ida in Patients with High-Risk Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) and MDS-Related Gene Mutations: A Subgroup Analysis of the UK NCRI AML19 Trial
59 - A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial
407 - Profiling Baseline Health-Related Quality of Life of Patients with Newly Diagnosed Myeloid Malignancies: A Pooled Analysis of 3349 Patients with AML, APL and MDS from the International Proactive Project
844 - The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3-ITD Mutations
845 - Impact of Cytogenetics, Induction Chemotherapy and MRD on Outcomes of Intensively Treated AML with KMT2A Rearrangements – Experience from UK NCRI AML17 and AML19
1830 - Genetic Diversity Drives Differing Morphological and Clinical Presentation and Survival in Myelodysplastic-Type CMML with a Low Absolute Monocyte Count
2907 - Gemtuzumab Based Induction Chemotherapy Combined with Midostaurin for FLT3 Mutated Patients. Results from the Patient- Reported Outcome Measures from the NCRI AML19V2 ‘Midotarg Pilot’
3805 - Patient-Reported Outcomes in Older Acute Myeloid Leukemia Patients Fit for Intensive Treatment, Who Received Intensified Treatment (DA +/- cladribine) Following No Evidence of Response to Course 1: Results from the NCRI AML18 Trial
Thomas, S. K.
767 - Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects
861 - Iopofosine I 131 in Previously Treated Patients with Waldenstrom Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM)
1021 - Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies
1584 - Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis
1654 - Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical
1922 - Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis
1923 - Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis
1971 - Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma
3024 - Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma
3272 - Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma
3344 - Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant
3764 - Association of Social Determinants of Health Status (SDOH) and Ethnicity with Survival in Multiple Myeloma Patients
4687 - Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
4737 - Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)
5154 - Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma
Thompson, A.
511 - An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel
513 - Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises
519 - Clinical Management Bundle for Patients with Sickle Cell Disease: Improving Completion of Age-Specific Screening Tests and Disease-Modifying Therapy Use
603 - Innovative Model for Creation and Use of Co-Developed Pain Management Plans for Patients with Sickle Cell Disease
709 - Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
1067 - Acceptability and Feasibility of Salivary Stress Research with Adolescents and Young Adults with Sickle Cell Disease
2194 - Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent β-Thalassemia
2313 - High Concordance between Investigator-Verified Diagnosis and Manual Data Abstraction for Sickle Cell Diagnosis Type: An ASH Research Collaborative Data Hub Validation Study
2691 - Outcomes of Immunosuppressive Therapy in Children Less Than Three Years of Age with Idiopathic Severe Aplastic Anemia: A North American Collaboration
3576 - Participants with a History of Stroke in Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials
3693 - Prospective Biopsychosocial Impacts of Stress and Disease Stigma Among Adolescents and Young Adults with Sickle Cell Disease
- Representing Sickle Cell Disease Health Concepts in Real World Evidence Generation: Examples from Real World Data (RWD) Initiatives and the Importance to the Sickle Cell Disease Community
- Landscape of SCD Treatment Options and New Therapies
Till, B. G.
783 - Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma: A Single-Center Retrospective Analysis
1616 - EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab
1666 - Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab + AVD in Untreated Classic Hodgkin Lymphoma
1667 - Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma
1684 - Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas
3043 - Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up
3051 - High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD
3069 - Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia
4395 - EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study
4431 - Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting
4832 - Gamma Secretase Inhibition May Mitigate the Impact of Low BCMA Target Density in Relapsed/Refractory Multiple Myeloma: Results from a Comparative Analysis of Two Phase 1 Clinical Trials
5116 - Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma
1661.2 - A Pilot Trial of Low Dose-Mosunetuzumab for Low-Tumor Burden Indolent B-Cell Lymphoma: Trial in Progress
4634.2 - Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL - the Avenue-2 Trial
Todisco, G.
104 - Clinical Relevance of the Integrative Analysis of Gut Microbiome and Metabolomics in Myeloid Neoplasms: Correlations with Genomic Profiles, Treatment Response/Complications and Clinical Outcome
105 - Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)
665 - Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
2221 - A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
3137 - Unveiling MED12L: A Potential Novel Orchestrator of Platelet Dysfunction in Myeloproliferative Myeloid Neoplasms
3194 - Single-Cell Multi-Omics Reveals Anticipated Erythroid Differentiation and Transcriptional Regulation in Differentiation Trajectories of SF3B1 - JAK2/MPL Mutated Cells in MDS/MPN-RS-T
3198 - Large-Scale Transcriptome Analysis Supports Genomic Taxonomy and Predicts Response to Hypomethylating Agents in Myelodysplastic Neoplasms
3597 - The “David Vs Goliath” Study: Application of Large Language Models (LLM) for Automatic Medical Information Retrieval from Multiple Data Sources to Accelerate Clinical and Translational Research in Hematology
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
4052 - Clonal Hematopoiesis and the Risk of Dementia: The Monzino 80-Plus Population-Based Study
4981 - Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
Tong, H.
663 - Decitabine Plus All-Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial
836 - Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial
1526 - Efficacy and Safety of Venetoclax Added to Arsenics Plus All-Trans-Retinoic Acid Combination Salvage Regimen for Patients with Relapsed/Refractory Acute Promyelocytic Leukemia
1630 - The Efficacy and Safety of Obinutuzumab with Zanubrutinib As First-Line Treatment in Older Patients with Mantle Cell Lymphoma
1733 - The ZR2-Minichop Study: Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin, and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
2701 - A Phase 2 Dose-Finding Trial of MY008211A in Complement Inhibitor–Naive Patients with Paroxysmal Nocturnal Hemoglobinuria and Signs of Active Hemolysis
4450 - Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study
4487 - Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma
4494 - Zanubrutinib in Combination with R-CHOP for Previously Untreated Mcd Type of Diffuse Large B-Cell Lymphoma (DLBCL)
4570 - HMGB3 As a Cargo Protein for XPO1: Implications for Myelodysplastic Syndromes Prognosis and Treatment
4575 - Single-Cell Transcriptomic Analysis Reveals Distinct Hematopoietic Landscapes and Immune Dysregulation in Der(1;7)(q10;p10) Myelodysplastic Syndromes
4685 - Pro-Inflammatory Monocytes As Key Effector Cells in Peripheral Circulatory Inflammatory Storms Driven By IFN-γ and IL-6 Pathways in Imcd
Torka, P.
398 - Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies
569 - Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin
652 - The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
1707 - High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease
2336 - Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
2344 - Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study
3647 - A Healthcare Utilization Model Comparing Time Toxicity between Glofitamab and Epcoritamab
4346 - Molecular Features Are Associated with Disease Stage in Diffuse Large B-Cell Lymphoma and Reveal Heterogeneity in Patient Outcomes
4429 - Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis
4451 - Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases
5101 - Impact of the Diagnosis-to-Treatment Interval (DTI) on Outcomes in Older Adults with Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Real-World Setting
- International Graduate Hematology
Tormo, M.
319 - Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study
320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry
1440 - Single-Agent Subcutaneous Blinatumomab for Advanced B-Cell Acute Lymphoblastic Leukemia: Long-Term Follow-up from a Phase 1b Dose Expansion Cohort
1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
1838 - Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial
3205 - Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia
3207 - Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial
4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML
Touzeau, C.
495 - Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm‑2 Studies
594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
774 - The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma
3282 - Voltage-Dependent Anion Channel 2 Controls Mitochondrial Priming through BAK Stabilization in Multiple Myeloma
3355 - Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)
3370 - First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)
4653 - Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies
4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)
4765 - Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)
Townsley, D.
Traer, E.
211 - Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia
662 - Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN)
1498 - Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients
1564 - Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial
2292 - Impact of Social Determinants of Health on Access to Blood and Marrow Transplantation for Acute Myeloid Leukemia
2859 - NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia
2887 - Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4312 - PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
4314 - Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML
4324 - Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
4325 - IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy
Treon, S. P.
743 - Single-Cell RNA Analysis of Bone Marrow Mononuclear Cells Reveals Abnormal Activation of T Cells and Monocytes, and Identifies CD35 As a Novel Biomarker and Therapeutic Target in Waldenstrom Macroglobulinemia
834 - Development and Characterization of Novel Dual HCK/BTK Bifunctional Protacs That Potently Inhibit Kinase Function and Demonstrate Robust in Vitro and In Vivo Degradation of Targets for the Treatment of MYD88-Mutated B-Cell Malignancies
860 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study
1647 - Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia
2968 - Multi-Omic Analysis Identifies Deletions in Chr17p and High ROR1 Expression, but Not TP53 Mutations As Predictors of Overall Survival in Patients with Untreated Waldenstrom’s Macroglobulinemia (WM)
2972 - Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström’s Macroglobulinemia and Represent Novel Therapeutic Targets.
2986 - Analysis of Alternative Splicing in Waldenstrom’s Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates
3011 - A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis
4338 - Genomic Evolution By Serial Single-Cell Sequencing Identifies High Tumor Expression of LYN As a Promoter of Resistance in Waldenstrom’s Macroglobulinemia Undergoing Ibrutinib Monotherapy
4358 - Expanded Genome-Wide Association Study (GWAS) Identifies Nine Novel Germline Risk Loci for Waldenström Macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL)
4359 - Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2- Inhibitors
4404 - A Phase II Trial of Loncastuximab Tesirine in Patients with Previously Treated Waldenström Macroglobulinemia
1661.1 - BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia
Tsakmaklis, N.
743 - Single-Cell RNA Analysis of Bone Marrow Mononuclear Cells Reveals Abnormal Activation of T Cells and Monocytes, and Identifies CD35 As a Novel Biomarker and Therapeutic Target in Waldenstrom Macroglobulinemia
834 - Development and Characterization of Novel Dual HCK/BTK Bifunctional Protacs That Potently Inhibit Kinase Function and Demonstrate Robust in Vitro and In Vivo Degradation of Targets for the Treatment of MYD88-Mutated B-Cell Malignancies
1647 - Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia
2968 - Multi-Omic Analysis Identifies Deletions in Chr17p and High ROR1 Expression, but Not TP53 Mutations As Predictors of Overall Survival in Patients with Untreated Waldenstrom’s Macroglobulinemia (WM)
2972 - Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström’s Macroglobulinemia and Represent Novel Therapeutic Targets.
2986 - Analysis of Alternative Splicing in Waldenstrom’s Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates
3011 - A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis
4338 - Genomic Evolution By Serial Single-Cell Sequencing Identifies High Tumor Expression of LYN As a Promoter of Resistance in Waldenstrom’s Macroglobulinemia Undergoing Ibrutinib Monotherapy
4359 - Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2- Inhibitors
Tucci, A.
82 - Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score
453 - B Cell Receptor Silencing Reveals Origin and Impacts Treatment of High-Grade B Cell Lymphomas with MYC and BCL2 Rearrangements
2464 - Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results
2863 - Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)
3016 - Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Marginal Zone Lymphoma: Results from the Phase 2 Bellwave-003 Study
3070 - Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
4449 - A Phase II Clinical Study Exploring the Safety and Efficacy of the Oral PI3Kδ Inhibitor, Linperlisib, in Relapsed Refractory T Cell Lymphoma
4473 - Impact of MYC Alterations in De Novo and Transformed Large B-Cell Lymphoma: An Italian Single Center Experience
3042.2 - Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy – MCL Elderly III
Tyner, J. W.
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z